PSA Blood Test UK: What It Measures, Normal Levels by Age & What a Raised Result Actually Means

What is PSA and why does it matter?

Prostate-specific antigen (PSA) is a protein produced by both normal and cancerous prostate cells. A small amount leaks into your bloodstream, and a simple blood test can measure how much is circulating. The result is reported in nanograms per millilitre (ng/ml).

PSA is not a cancer test. It is a prostate health marker. A raised level can signal prostate cancer, but it can also be caused by an enlarged prostate (benign prostatic hyperplasia, or BPH), a urinary infection, prostatitis, or even vigorous exercise. Conversely, around one in seven men with a “normal” PSA may still harbour prostate cancer — a false-negative rate that makes the test useful but imperfect.

Despite these limitations, PSA testing remains the most widely available first-line screening tool for prostate cancer in the UK. Prostate cancer is now the most commonly diagnosed cancer in men, with over 52,000 new cases per year in the UK and roughly 12,000 deaths annually — more than breast cancer deaths in women. Cancer Research UK estimates that 1 in 8 men will be diagnosed in their lifetime.

Who should get a PSA blood test?

The UK has no formal prostate cancer screening programme. The NHS Prostate Cancer Risk Management Programme (PCRMP) entitles any man aged 50 or over to request a PSA test from their GP after an informed-choice conversation, even if they have no symptoms.

You should consider testing earlier — from age 45 — if:

• Your father, brother, or son has been diagnosed with prostate cancer
• You are Black African or Black Caribbean — risk is approximately double
• You carry a BRCA1 or BRCA2 mutation (the UK National Screening Committee now recommends annual PSA from age 40 for BRCA2 carriers)
• You have Lynch syndrome (hereditary nonpolyposis colorectal cancer)
• You have lower urinary tract symptoms: weak flow, frequency, nocturia, hesitancy

For men under 45 with no risk factors, routine PSA testing is not currently recommended because the rate of false positives outweighs the benefit. However, a baseline PSA measurement in your 40s is increasingly advocated by urologists — the European Randomised Study of Screening for Prostate Cancer (ERSPC) found that a man's PSA at age 44–50 is a powerful predictor of future prostate cancer risk, even if the initial level is normal.

Normal PSA levels by age

PSA rises naturally with age as the prostate grows. There is no single “normal” threshold — instead, age-specific reference ranges are used to interpret results. NICE and British Association of Urological Surgeons (BAUS) guidelines use these thresholds to decide whether further investigation is warranted:

Source: Prostate Cancer Risk Management Programme (PCRMP) & NICE NG131. Thresholds may differ slightly between labs.

These thresholds are not diagnostic cut-offs. A PSA of 3.5 ng/ml in a 50-year-old does not mean cancer. It means the probability is high enough to warrant further investigation — typically a repeat test in 6–8 weeks, followed by an MRI if the level persists.

Why ethnicity changes the risk equation

Black men in the UK are approximately twice as likely to be diagnosed with prostate cancer as white men, and they are diagnosed at a younger age on average. The reasons are multifactorial: genetic variants in androgen receptor sensitivity, higher circulating testosterone levels in some populations, and socioeconomic disparities in access to testing all play a role.

The Prostate Cancer UK PROCESS study (2023) found that 1 in 4 Black men over 50 who underwent screening had clinically significant prostate cancer, compared to roughly 1 in 8 in the general population.

What this means practically: if you are Black, your GP should take a PSA result of 2.5 ng/ml at age 45 more seriously than the same result in a white man of the same age. If your GP dismisses a raised result, you are entitled to ask for a urology referral under the two-week cancer pathway.

Asian men have a lower overall incidence of prostate cancer in the UK, though the gap is narrowing with lifestyle westernisation. Regardless of ethnicity, family history remains the strongest single risk factor after age.

Free PSA, PSA density and advanced variants

A total PSA test measures all PSA in your blood — both the portion bound to proteins and the portion circulating freely. But total PSA alone cannot distinguish between cancer and benign causes. That is where advanced PSA metrics help:

None of these tests replace the need for an MRI if your standard PSA is raised. They are refinement tools that help urologists decide whether a biopsy is justified after imaging.

PSA velocity: why the trend matters more than the number

A single PSA measurement is a snapshot. PSA velocity — the rate at which your PSA changes over time — is often more clinically meaningful than any individual reading.

A rise of more than 0.75 ng/ml per year is considered significant, regardless of whether the absolute value is above or below the age-specific threshold. A man whose PSA moves from 1.8 to 3.2 over 18 months (velocity of approximately 1.1 ng/ml/year) warrants investigation, even though neither reading alone would trigger a referral in a 55-year-old.

This is why a baseline PSA measurement in your 40s is so valuable. Without a starting point, your GP has no velocity to calculate. The European Association of Urology (EAU) and the European Randomised Study of Screening for Prostate Cancer (ERSPC) both support early baseline testing for this reason.

Practical takeaway: if your PSA is in the normal range, repeat the test every 2–4 years. If it is above the median for your age, repeat annually. If your velocity exceeds 0.75 ng/ml/year at any point, ask for a urology referral regardless of the absolute number.

What can raise your PSA (that isn't cancer)

Before you panic over a raised result, know that many benign factors can push PSA up. Your GP should consider all of these before referring you for investigation:

The finasteride point is critical. If you take finasteride (Propecia) for hair loss or dutasteride (Avodart) for an enlarged prostate, your GP must double your reported PSA to get a true estimate. This is a common source of false reassurance.

Similarly, obesity can artificially lower PSA through haemodilution. If you have a high BMI and any urinary symptoms, push for investigation even if your PSA appears normal.

How to prepare for a PSA blood test

PSA is a simple venous blood draw — no fasting required. But several factors can artificially raise your result, so observe these preparation rules for the most accurate reading:

• Avoid ejaculation for 48 hours before the blood draw
• Avoid vigorous exercise — particularly cycling — for 48 hours
• If you have a urinary infection, wait until it is fully treated before testing
• If you have had a digital rectal examination, wait at least one week
• If you have had a urological procedure (catheter, biopsy, cystoscopy), wait at least six weeks
• Tell the phlebotomist if you take finasteride, dutasteride, or any 5-alpha-reductase inhibitor

Results typically take 1–5 working days depending on the laboratory. NHS GP tests may take up to two weeks. Private labs usually return results within 2–5 days.

What happens after a raised PSA result

A raised PSA does not mean you have prostate cancer. Approximately 75% of men with a raised PSA will not have cancer on further investigation. But it does mean your GP should initiate a structured pathway. Here is what that looks like in the NHS in 2026:

The entire pathway from first raised PSA to histology result typically takes 6–12 weeks. If your GP does not initiate a referral after a confirmed raised PSA, you are entitled to request one directly. NICE NG12 is clear on this.

The MRI-first pathway explained

Before 2019, a raised PSA typically led straight to a biopsy — an invasive procedure with a meaningful risk of infection and overdiagnosis. The landmark PROMIS trial (The Lancet, 2017) and the subsequent PRECISION trial (NEJM, 2018) changed everything.

These trials demonstrated that multiparametric MRI (mpMRI) could safely rule out clinically significant prostate cancer in approximately 27% of men, sparing them an unnecessary biopsy entirely. When biopsy was needed, MRI-targeted biopsies detected 12% more clinically significant cancers than standard systematic biopsies, while also finding 13% fewer insignificant cancers (the kind that would have led to overtreatment).

NICE updated its guidelines ( NG131) to recommend mpMRI before any first biopsy. The PI-RADS scoring system grades MRI findings from 1 (clinically significant cancer highly unlikely) to 5 (clinically significant cancer highly likely):

The MRI-first pathway has been one of the most significant advances in prostate cancer diagnosis in the last decade. If your urologist suggests biopsy without first performing an MRI, ask why.

Getting tested: NHS vs private options

If your GP declines a PSA test, know your rights. The PCRMP guarantees any man aged 50 or over the right to request one after an informed-choice discussion. If you are under 50 but have risk factors, present them clearly. GPs are not obliged to test asymptomatic men under 50, but they should consider it in the context of your personal risk profile.

A private blood test gives you the advantage of establishing a baseline before you reach the conventional screening age. Combine PSA with a broader health panel to get context: your testosterone, inflammation markers, and metabolic profile all interact with prostate health.

What else to test alongside PSA

PSA in isolation tells you about one organ. A comprehensive blood panel puts prostate health in the context of your whole body. If you are testing PSA, it makes sense to also check:

• Testosterone (total and free) — Low testosterone is linked to more aggressive prostate cancer phenotypes. High testosterone does not cause prostate cancer — the relationship is more nuanced than the old myth suggests.
• SHBG — Sex hormone-binding globulin modulates how much free testosterone reaches tissues, including the prostate. Low SHBG may amplify androgenic signalling.
• hs-CRP — Chronic inflammation is associated with prostate cancer progression. An elevated hs-CRP alongside a borderline PSA adds context that total PSA alone cannot.
• Vitamin D — Observational studies consistently link low vitamin D to higher prostate cancer risk. The relationship is not yet proven causal, but insufficiency is worth correcting regardless.
• IGF-1 — Insulin-like growth factor 1 has a complex relationship with prostate cancer: higher circulating levels are associated with increased risk in epidemiological data.
• HbA1c and fasting insulin — Metabolic health matters. Insulin resistance and type 2 diabetes are associated with more aggressive prostate cancer, and men with diabetes may have artificially lower PSA levels.

Frequently asked questions

Sources

1. NICE NG131 — Prostate cancer: diagnosis and management (2019, updated 2024)
2. NICE NG12 — Suspected cancer: recognition and referral (2023 update)
3. Cancer Research UK — Prostate cancer statistics
4. Prostate Cancer UK — PSA blood test
5. NHS PCRMP — Prostate Cancer Risk Management Programme
6. Ahmed et al. (2017) PROMIS trial — The Lancet
7. Kasivisvanathan et al. (2018) PRECISION trial — NEJM
8. Loeb et al. (2015) — Prostate Health Index for cancer detection, European Urology
9. BMJ (2019) — Prostate cancer screening: weighing the evidence
10. Prostate Cancer UK — PROCESS study and ethnic risk data